Intra-Cellular Therapies, Inc. (ITCI)

NASDAQ: ITCI · IEX Real-Time Price · USD

74.86

-0.08 (-0.11%)

At close: Jul 19, 2024, 4:00 PM

74.25

-0.61 (-0.81%)

Pre-market: Jul 22, 2024, 8:57 AM EDT

Intra-Cellular Therapies Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2011
Net Income	-110.87	-139.67	-256.26	-284.13	-227.01	-147.72	Upgrade
Depreciation & Amortization	0.53	0.53	0.66	0.53	0.53	0.48	Upgrade
Share-Based Compensation	56.33	52.92	43.1	34.48	24.33	20.98	Upgrade
Other Operating Activities	-44.24	-37.98	-57.69	-10.43	-27.92	-1.72	Upgrade
Operating Cash Flow	-98.25	-124.2	-270.19	-259.54	-230.07	-127.98	Upgrade
Capital Expenditures	-0.27	-0.27	-0.78	-0.33	-0.27	-0.7	Upgrade
Change in Investments	138.45	105.81	-127.6	280.67	-480.03	178.14	Upgrade
Investing Cash Flow	138.18	105.54	-128.37	280.34	-480.3	177.44	Upgrade
Share Issuance / Repurchase	24.16	17.81	455.16	11.52	664.18	3.24	Upgrade
Financing Cash Flow	24.16	17.81	455.16	11.52	664.18	3.24	Upgrade
Net Cash Flow	64.09	-0.85	56.6	32.32	-46.19	52.69	Upgrade
Free Cash Flow	-98.52	-124.47	-270.96	-259.87	-230.34	-128.68	Upgrade
Free Cash Flow Margin	-19.17%	-26.80%	-108.25%	-310.10%	-1009.69%	-212303.69%	Upgrade
Free Cash Flow Per Share	-1.02	-1.30	-2.88	-3.20	-3.27	-2.33	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).